Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 58.51 USD -2.9% Market Closed
Market Cap: 9.1B USD

Intrinsic Value

The intrinsic value of one TECH stock under the Base Case scenario is 55.17 USD. Compared to the current market price of 58.51 USD, Bio-Techne Corp is Overvalued by 6%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TECH Intrinsic Value
55.17 USD
Overvaluation 6%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Bio-Techne Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about TECH?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is TECH valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Bio-Techne Corp.

Explain Valuation
Compare TECH to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Academic and pharma research spending cuts could significantly reduce demand for Bio-Techne’s core reagent and assay products, exacerbating top-line pressure given its sizable exposure to these often cyclical customer segments.

With larger rivals like Danaher and Thermo Fisher expanding aggressively into proteomics and cell biology tools, Bio-Techne risks losing market share if it cannot sustain differentiation through innovation in areas like single-cell analysis.

A heavy reliance on acquisitions to broaden its product portfolio may strain Bio-Techne’s resources and hamper profitability if integration costs rise or synergistic benefits fail to materialize as planned.

Bull Theses

Its extensive catalog of specialized reagents, assays, and instruments positions Bio-Techne to capitalize on accelerating interest in high-growth areas such as precision medicine and gene therapy research.

With recurring revenue streams from consumables and strong global distribution networks, Bio-Techne secures a predictable cash flow that can be reinvested into R&D and product development for emerging life sciences applications.

Longstanding success in integrating acquired businesses like Advanced Cell Diagnostics demonstrates Bio-Techne’s ability to expand effectively into novel technologies—signaling a potential for continued M&A-driven growth and market share gains.

Show More Less
How do you feel about TECH?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bio-Techne Corp

Current Assets 609.5m
Cash & Short-Term Investments 145m
Receivables 183.9m
Other Current Assets 280.6m
Non-Current Assets 1.9B
Long-Term Investments 249.9m
PP&E 311.1m
Intangibles 1.3B
Other Non-Current Assets 26.6m
Current Liabilities 144.5m
Accounts Payable 30.2m
Accrued Liabilities 76.5m
Other Current Liabilities 37.8m
Non-Current Liabilities 415.8m
Long-Term Debt 300m
Other Non-Current Liabilities 115.8m
Efficiency

Free Cash Flow Analysis
Bio-Techne Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Bio-Techne Corp

Revenue
1.2B USD
Cost of Revenue
-403.6m USD
Gross Profit
813.2m USD
Operating Expenses
-544m USD
Operating Income
269.2m USD
Other Expenses
-192.4m USD
Net Income
76.8m USD
Fundamental Scores

TECH Profitability Score
Profitability Due Diligence

Bio-Techne Corp's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Healthy Operating Margin
Sustainable 3Y Average Operating Margin
50/100
Profitability
Score

Bio-Techne Corp's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

TECH Solvency Score
Solvency Due Diligence

Bio-Techne Corp's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
84/100
Solvency
Score

Bio-Techne Corp's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TECH Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TECH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECH is 70.79 USD with a low forecast of 60.6 USD and a high forecast of 78.75 USD.

Lowest
Price Target
60.6 USD
4% Upside
Average
Price Target
70.79 USD
21% Upside
Highest
Price Target
78.75 USD
35% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for TECH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

TECH Insider Trading
Buy and sell transactions by insiders

TECH News

Other Videos
What is the Intrinsic Value of one TECH stock?

The intrinsic value of one TECH stock under the Base Case scenario is 55.17 USD.

Is TECH stock undervalued or overvalued?

Compared to the current market price of 58.51 USD, Bio-Techne Corp is Overvalued by 6%.

Back to Top